Venlor (Venlafaxine)

$ 124.52$ 267.90

Category: Anti-Depressants
Commercial name: Venlor
Active ingredient: Venlafaxine
Production form: Pills
Available dosage: 75 mg



Venlor. Dosage, Side Effects, Interactions

Venlor (Venlafaxine) belongs to the group of antidepressants. Depending on the substance, antidepressants generally have a depression-relieving, mood-enhancing, psychomotor-activating or depressant effect. A clinically relevant antidepressant effect can only be expected about two to three weeks after the start of therapy, while a number of side effects occur without a corresponding latency. 

General information about Venlor (Venlafaxine)

One group of antidepressants includes the selective serotonin-norepinephrine reuptake inhibitors (SSNRI; sometimes also abbreviated as SNRI). Like tricyclic antidepressants (TCAs), they inhibit the reuptake of serotonin and norepinephrine. However, they do not show any relevant affinity for adrenergic, cholinergic or histaminergic receptors. They have an antidepressant and drive-enhancing effect, but do not have a sedating effect.

Venlafaxine and its active metabolite, O-desmethylvenlafaxine, exclusively inhibit reuptake and do not block receptors. Serotonin reuptake inhibition is very pronounced, while norepinephrine reuptake inhibition is very weak. Venlafaxine does not inhibit dopamine reuptake at all.

Application and dosage of Venlor (Venlafaxine)

Venlafaxine is used to treat and prevent the recurrence of major depressive episodes. In addition, the drug is recommended as a first-line drug in patients with generalized anxiety disorder.

Venlafaxine is recommended in addition to generalized anxiety disorder for patients over the age of 18, including panic disorder, agoraphobia and social phobia.

The dosage of venlafaxine is between 75 and 225 mg for all indications. The initial daily dose of venlafaxine is 75 mg and the maximum daily dose is 375 mg. The dosage depends on the type and severity of the disease.

Prolonged-release venlafaxine can be given once a day, with non-prolonged-release venlafaxine the daily dose should be divided into 2 to 3 divided doses. It is preferably taken with a meal.

To avoid discontinuation symptoms, abrupt discontinuation of therapy should be avoided. Therefore, when stopping treatment with venlafaxine, the dose is gradually reduced over a period of at least one to two weeks.

However, even with tapering therapy, withdrawal symptoms can occur up to four weeks after the end of treatment. These include above all:

  • Mental changes (anxiety, agitation, confusion, drowsiness, impaired perception)
  • Neurological disorders (headache, dysgeusia, dizziness, tremor)
  • Vegetative disorders (dry mouth, sweating)
  • visual disturbances
  • tinnitus
  • anorexia
  • diarrhea

Side effects of Venlor (Venlafaxine)

The most commonly reported side effects in clinical trials were nausea, dry mouth, headache and sweating.

Other common side effects that may occur (selection):

  • decreased appetite
  • confusion
  • depersonalization
  • unusual dream content
  • nervousness
  • libido decrease
  • agitation
  • Tremble
  • paresthesias
  • visual disturbances
  • accommodation disorders
  • tinnitus


Since cases of QT interval prolongation have been described with the use of venlafaxine, concomitant use of drugs that also have a prolonging effect on the QT interval should be avoided.

This includes e.g. B. the following drug classes:

  • Class Ia and III antiarrhythmics (eg, quinidine, amiodarone, sotalol)
  • Macrolides (e.g. erythromycin)
  • Quinolone antibiotics (e.g. moxifloxacin)

Serotonin Syndrome

A potentially life-threatening serotonin syndrome can occur during treatment with venlafaxine. Reactions similar to neuroleptic malignant syndrome (NMS) can also occur. The danger is particularly high with concomitant use of other serotonergic agents (including SSRIs, SNRIs and triptans). Also with active substances that impair the metabolism of serotonin, e.g. B. MAO inhibitors, neuroleptics or dopamine antagonists.

The symptoms of serotonin syndrome can be expressed as follows:

  • Mental status changes (eg, agitation, hallucination, coma)
  • autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia)
  • neuromuscular abnormalities (eg, hyperreflexia, incoordination)
  • gastrointestinal symptoms (eg, nausea, vomiting, diarrhea)

Therefore, these combinations are considered contraindicated.

Patients with impaired kidney and liver function

Although no change in dosage is required in patients with a glomerular filtration rate (GFR) of 30 to 70 mL/minute, caution is advised. In patients requiring hemodialysis and in patients with severe renal impairment (GFR < 30 ml/min), the dose should be reduced by 50 percent.

A dose reduction of 50 percent should be considered in patients with mild or moderate hepatic impairment.

Pregnancy and breast feeding period

There are no adequate data from the use of venlafaxine in pregnant women. The active substance may only be used in this patient group if the expected benefit outweighs the possible risks. Embryotox sees sertraline or citalopram as more suitable alternatives , provided that a changeover is possible under medical supervision.

Breastfeeding is conditionally acceptable with good supervision of the child. However, the decision to take venlafaxine while breastfeeding should be carefully considered.

Looking where to buy Venlor (Venlafaxine) online without a prescription? Order now on our website!  We deliver orders all over United States. The best drug prices are only available in our authorized online pharmacy

Additional information


75 mg


30, 60, 90, 120, 180


There are no reviews yet.

Be the first to review “Venlor (Venlafaxine)”

Your email address will not be published.